Table 3 Patient and tumor characteristics by a total dose of external beam radiation therapy (EBRT) alone
From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
<70 Gy | 70–74 Gy | 75+ Gy | ||||
|---|---|---|---|---|---|---|
Characteristics | (%)* | Patients (n)† | (%)* | Patients (n)† | (%)* | Patients (n)† |
Total‡, n = 4611 (1636) | 53.0 | 2444 (920) | 25.0 | 1152 (382) | 22.0 | 1015 (334) |
States (p < 0.0001)§ | ||||||
A | 32.2 | 369 (100) | 41.5 | 476 (125) | 26.3 | 302 (69) |
B | 74.3 | 645 (293) | 9.8 | 85 (39) | 15.9 | 138 (69) |
C | 58.5 | 204 (57) | 27.5 | 96 (28) | 14.0 | 49 (13) |
D | 57.7 | 253 (166) | 26.7 | 117 (78) | 15.6 | 68 (45) |
E | 46.2 | 188 (74) | 13.0 | 53 (19) | 40.8 | 167 (48) |
F | 59.5 | 584 (157) | 22.4 | 221 (52) | 18.1 | 177 (50) |
G | 48.0 | 201 (73) | 24.8 | 104 (41) | 27.2 | 114 (40) |
Age (y) (p = 0.0156)§ | ||||||
20–59 | 64.6 | 345 (131) | 15.2 | 81 (33) | 20.2 | 108 (37) |
60–69 | 53.5 | 837 (338) | 25.5 | 400 (141) | 21.0 | 330 (127) |
70+ | 50.3 | 1262 (451) | 26.7 | 671 (208) | 23.0 | 577 (170) |
Race (p < 0.0001)§ | ||||||
White, non-hispanic (NH) | 53.5 | 1706 (508) | 24.4 | 777 (190) | 22.1 | 703 (183) |
Black, NH | 59.8 | 603 (332) | 21.2 | 213 (123) | 19.0 | 191 (106) |
Hispanic | 32.1 | 93 (52) | 38.8 | 112 (38) | 29.1 | 84 (23) |
Asians/others | 32.9 | 42 (28) | 38.5 | 50 (31) | 28.6 | 37 (22) |
Marital status (p = 0.8262)§ | ||||||
Single | 55.0 | 586 (238) | 23.8 | 253 (92) | 21.2 | 225 (84) |
Married | 53.2 | 1773 (649) | 23.8 | 795 (263) | 23.0 | 766 (243) |
Education¶ (p = 0.0279)§ | ||||||
Not undereducated | 50.8 | 1417 (481) | 24.6 | 685 (200) | 24.6 | 688 (195) |
Undereducated | 56.3 | 1014 (435) | 25.8 | 464 (181) | 17.9 | 323 (138) |
Working class (p = 0.0910)§ | ||||||
Not working class | 48.9 | 908 (312) | 26.3 | 487 (133) | 24.8 | 461 (127) |
Working class | 55.7 | 1522 (604) | 24.2 | 662 (248) | 20.1 | 550 (206) |
Urbanization (p = 0.0293)§ | ||||||
Urban | 47.6 | 1023 (400) | 28.3 | 608 (200) | 24.1 | 519 (165) |
Rural | 57.4 | 454 (165) | 22.7 | 179 (64) | 19.9 | 157 (57) |
Urban-Rural mix | 57.8 | 954 (351) | 21.9 | 362 (117) | 20.3 | 335 (111) |
Poverty level (p = 0.0255)§ | ||||||
Not in poverty level | 51.6 | 1870 (644) | 24.9 | 904 (268) | 23.5 | 852 (254) |
In poverty level | 58.1 | 561 (272) | 25.4 | 245 (113) | 16.5 | 159 (79) |
Health insurance (p = 0.0036)§ | ||||||
Not insured | 58.7 | 46 (22) | 22.7 | 18 (6) | 18.6 | 14 (7) |
Public coverage | 56.9 | 1732 (664) | 20.9 | 637 (229) | 22.2 | 674 (232) |
Private coverage | 45.1 | 519 (179) | 36.4 | 418 (117) | 18.5 | 212 (65) |
Insurance, NOS | 61.6 | 87 (33) | 16.5 | 23 (11) | 21.9 | 31 (10) |
Piccirillo comorbidity score (p = 0.0800)§ | ||||||
None | 50.5 | 613 (221) | 25.5 | 310 (94) | 24.0 | 291 (88) |
Mild | 52.2 | 1273 (492) | 24.8 | 604 (213) | 23.0 | 560 (188) |
Moderate | 60.3 | 378 (143) | 19.1 | 120 (44) | 20.6 | 129 (42) |
Severe | 65.1 | 119 (46) | 23.4 | 43 (11) | 11.5 | 21 (10) |
PSA (ng/ml) (p = 0.0016)§ | ||||||
<10 | 50.0 | 1446 (533) | 27.3 | 787 (256) | 22.7 | 656 (210) |
10–20 | 53.7 | 556 (215) | 21.2 | 220 (74) | 25.1 | 259 (81) |
>20 | 65.1 | 408 (158) | 21.0 | 131 (49) | 13.9 | 87 (40) |
Clinical T stage (p = 0.1833)§ | ||||||
Tx-T0 | 26.1 | 9 (4) | 24.3 | 9 (4) | 49.6 | 18 (5) |
T1 | 52.1 | 1477 (569) | 26.2 | 741 (252) | 21.7 | 613 (197) |
T2 | 53.7 | 825 (299) | 24.4 | 376 (115) | 21.9 | 336 (115) |
T3-T4 | 64.4 | 133 (48) | 12.8 | 26 (11) | 22.8 | 47 (17) |
Gleason score (p = 0.0007)§ | ||||||
2–6 | 46.9 | 1033 (385) | 30.5 | 670 (218) | 22.6 | 498 (163) |
7 | 57.6 | 958 (361) | 20.5 | 341 (115) | 21.9 | 365 (119) |
8–10 | 61.4 | 441 (169) | 17.8 | 128 (46) | 20.8 | 150 (50) |
Recurrence risk group (p = 0.0001)§ | ||||||
LR | 44.3 | 620 (229) | 34.0 | 477 (155) | 21.7 | 304 (101) |
IR | 53.8 | 1071 (401) | 21.9 | 435 (143) | 24.3 | 484 (150) |
HR | 61.8 | 753 (290) | 19.7 | 241 (84) | 18.5 | 226 (83) |